Home / Science / Zydus: Early Pioneer in Obesity Drug Race

Zydus: Early Pioneer in Obesity Drug Race

4 Mar

Summary

Zydus scientists achieved early success with an oral GLP-1 agonist.
This development predates the current boom in popular obesity drugs.
The drug was coded ZYOG1, marking Zydus's innovative pipeline effort.

Fifteen years before the current surge in popularity for obesity drugs such as Ozempic and Mounjaro, Zydus Lifesciences had already achieved an early success. A group of scientists at the Indian pharmaceutical company developed an oral GLP-1 agonist, identified by the code ZYOG1.

This initiative was part of Zydus's ambitious strategy to build a pipeline of innovative drugs. At that time, the market impact of obesity drugs was not yet established, and many larger companies were concentrating their research efforts on anti-diabetes medications.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.